Switching to Aflibercept in Diabetic Macular Edema after Unsatisfactory Response to Other Anti-vascular Endothelial Growth Factor Drugs
Korean Journal of Ophthalmology
;
: 122-130, 2019.
Article
in English
| WPRIM
| ID: wpr-741318
ABSTRACT
PURPOSE:
To evaluate the efficacy of switching to aflibercept in diabetic macular edema (DME) with suboptimal response to previous anti-vascular endothelial growth factor (anti-VEGF) injections.METHODS:
A prospective interventional case series study recruited patients from a single center diagnosed with DME with suboptimal response to anti-VEGF injections. Three consecutive monthly injections of aflibercept were performed. The primary outcome measure was mean change in visual acuity after switching to aflibercept.RESULTS:
Forty-two patients (42 eyes) were included. Baseline logarithm of the minimum angle of resolution (logMAR) visual acuity was 0.87 ± 0.23 and improved significantly to 0.62 ± 0.29, 0.56 ± 0.34, and 0.46 ± 0.35 at 1, 2, and 3 months, respectively, after the first injection. Mean baseline retinal thickness was 451.57 ± 107.09 µm and decreased significantly at 1, 2, and 3 months after switching to aflibercept (346.52 ± 79.03, 328.24 ± 81.98, and 313.71 ± 85.79 µm, respectively). Both visual improvement and mean change in retinal thickness were significant in patients with pre-aflibercept best-corrected visual acuity less than 1.0 logMAR but were not significant in patients with best-corrected visual acuity more than 1.0 logMAR.CONCLUSIONS:
Switching to aflibercept in DME patients with an unsatisfactory response to previous anti-VEGF injections provided acceptable short-term visual and retinal architectural improvement.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Retinaldehyde
/
Visual Acuity
/
Macular Edema
/
Prospective Studies
/
Endothelial Growth Factors
/
Outcome Assessment, Health Care
/
Diabetic Retinopathy
Type of study:
Observational study
Limits:
Humans
Language:
English
Journal:
Korean Journal of Ophthalmology
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS